IP Library Granted Patent US 10,829,445
Granted Patent B2
US 10,829,445 · App. 16/685,534 · Granted Nov 10, 2020

N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors

Inventors: John P. Toscano (Glen Arm, MD); Frederick Arthur Brookfield (Abingdon, GB); Andrew D. Cohen (Mamaroneck, NY); Stephen Martin Courtney (Abingdon, GB); Lisa Marie Frost (Abingdon, GB); Vincent Jacob Kalish (Annapolis, MD)
Assignees: Cardioxyl Pharmaceuticals, Inc.; The Johns Hopkins University
C07C311/48C07C317/14C07C323/67C07D213/74C07D231/18C07D261/10C07D263/58C07D285/125C07D295/096C07D307/82C07D309/12C07D317/14C07D333/34C07D333/62Y02A50/414
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,829,445
App. No.
16/685,534
Granted
Nov 10, 2020
Kind
B2
Abstract

The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release HNO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.

Claims (34)

1. A method of preparing a compound of the formula (III)

or a pharmaceutically acceptable salt thereof, wherein

R 1 is H;

R 2 is H;

n is 0;

b is an integer from 1 to 4;

each R 8 is independently selected from halo, CF 3 , NO 2 , CN, phenyl, (C 1 -C 8 )alkyl, SO 2 NHOH, SO 2 CH 3 , SO 2 phenyl, C(O)O(C 1 -C 4 )alkyl, and C(O)morpholino; and

Q 9 , Q 11 , Q 12 , Q 13 and Q 14 are defined such that ring C is furan or thiophene;

the method comprising reacting a compound of formula A1 with hydroxylamine hydrochloride, wherein the compound of formula A1 has the structure:

and R is furan or thiophene and is substituted with 1 to 4 R 8 .

2. The method of claim 1 , wherein, in the compound of formula (III), each R 8 is independently selected from F, Br, Cl, CF 3 , phenyl, methyl, SO 2 NHOH, and C(O)O(C 1 -C 4 )alkyl.

3. The method of claim 2 , wherein, in the compound of formula (III), R 8 is methyl and ring C is furan.

4. A method of preparing a compound of the formula (III)

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is H;

R 2 is H;

n is 0;

b is 1;

R 8 is Cl, Br, nitro, methyl or cyano; and

Q 9 , Q 11 , Q 12 , Q 13 and Q 14 are defined such that ring C is furan or thiophene;

the method comprising reacting a compound of formula A1 with hydroxylamine hydrochloride, wherein the compound of formula A1 has the structure:

and R is furan or thiophene and is substituted with 1 R 8 .

5. The method of claim 4 , wherein, in the compound of formula (III), R 8 is methyl and ring C is furan.

6. A method of preparing a compound which is:

or a pharmaceutically acceptable salt thereof, the method comprising reacting a compound of formula A1 with hydroxylamine hydrochloride, wherein the compound of formula A1 has the structure:

and is 3,5-dimethylisoxazole-4-sulfonyl chloride.

7. A method of preparing a compound which is:

or a pharmaceutically acceptable salt thereof,

the method comprising reacting a compound of formula A1 with hydroxylamine hydrochloride, wherein the compound of formula A1 has the structure:

and is 1-methyl-1H-pyrazole-3-sulfonyl chloride.

8. A method of preparing a compound which is

or a pharmaceutically acceptable salt thereof,

the method comprising reacting a compound of formula A1 with hydroxylamine hydrochloride, wherein the compound of formula A1 has the structure:

and is 4-bromothiophene-3-sulfonyl chloride, 3-bromothiophene-2-sulfonyl chloride, 4-bromo-2,5-dichlorothiophene-3-sulfonyl chloride or 4-phenyl-5-(trifluoromethyl)thiophene-3-sulfonyl chloride.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2022
From: CARDIOXYL PHARMACEUTICALS INC.
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 062041/0565 →
CONFIRMATORY LICENSE Recorded Apr 17, 2020
From: JOHNS HOPKINS UNIVERSITY
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 052430/0725 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: KALISH, VINCENT JACOB
To: CARDIOXYL PHARMACEUTICALS
Reel/Frame 051233/0965 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: TOSCANO, JOHN P.; COHEN, ANDREW D.
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 051233/0996 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: BROOKFIELD, FREDERICK ARTHUR; COURTNEY, STEPHEN MARTIN; FROST, LISA MARIE
To: EVOTEC LTD
Reel/Frame 051234/0050 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2019
From: EVOTEC LTD
To: CARDIOXYL PHARMACEUTICALS
Reel/Frame 051234/0169 →
Continuity (10)
Continuation 16243251 · Jan 9, 2019
Continuation 15961441 · Apr 24, 2018
Continuation 15640342 · Jun 30, 2017
Continuation 15286145 · Oct 5, 2016
Continuation 14857308 · Sep 17, 2015
Continuation 14280133 · May 16, 2014
Continuation 13213480 · Aug 19, 2011
Continuation 11724792 · Mar 16, 2007
Provisional Application 60783556 · Mar 17, 2006
Related Publication 20200087253A1 · Mar 19, 2020
Cited By (1)
US 12,186,301